The recent first global approval of anlotinib has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2].

In May 2018, anlotinib (Focus V®), co-developed by Jiangsu Chia-Tai Tianqing Pharmaceutical and Advenchen Laboratories, received its first global approval in China as a single drug therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have undergone progression or recurrence after ≥ 2 lines of systemic chemotherapy. 

The drug is an orally administered small molecule multi-target tyrosine kinase inhibitors including vascular endothelial growth factor receptors (VEGFR) 2 and 3, fibroblast growth factor receptors (FGFR) 1–4, platelet-derived growth factor receptors (PDGFR) α and β, c-Kit and Ret that play a role in tumor angiogenesis and growth in this complex disease.

Anlotinib os also under clinical investigation in the US, China and Italy for a number of soft tissue cancers. [2]

Please visit Drugs[1]  or AdisInsight[2] for further information related to the first approval, and overall on-going clinical development, respectively, of anlotinib.

Image credit:  Jonathan Perez – Unsplash

Leave a Reply